Inmed Pharmaceuticals INC Form 4 insider transactions

InMed Pharmaceuticals and Mentari Therapeutics announce a merger to advance novel migraine prevention therapies, backed by significant private placement funding.

InMed Pharmaceuticals Inc. and Mentari Therapeutics, Inc. announced an amendment to their merger agreement, increasing Mentari's pre-closing private placement financing to $200 million.

Mentari Therapeutics announces Greg Divis as new CEO, advancing migraine therapies as it merges with InMed Pharmaceuticals.

ADAR1 Capital Management, LLC and 1 other reported changes in beneficial ownership of InMed Pharmaceuticals Inc. common stock on July 15, 2026.

Vivo Opportunity, LLC and 3 others reported changes in beneficial ownership of InMed Pharmaceuticals Inc. common stock on July 14, 2026.

InMed Pharmaceuticals and Mentari Therapeutics have amended their merger agreement, clarifying transaction sequencing, pre-closing financing impacts, and tax treatment, while also filing a Form S-4 registration statement.

Vivo Opportunity, LLC and its affiliated entities report acquiring a significant number of InMed Pharmaceuticals Inc. common shares between June 30 and July 2, 2026.

Vivo Opportunity, LLC has reported a series of open market purchases increasing its beneficial ownership in InMed Pharmaceuticals Inc.

ADAR1 Capital Management, LLC and Daniel Schneeberger reported the acquisition of 468,551 common shares of InMed Pharmaceuticals Inc. on May 19, 2026.

InMed Pharmaceuticals Inc. announced a definitive merger agreement with Mentari Therapeutics, Inc., a biotechnology company focused on migraine prevention therapies, in an all-stock transaction.

InMed Pharmaceuticals Inc. has granted 8,500 employee stock options to Shane Aaron Johnson, Senior VP & General Manager, with an exercise price of $1.29.

InMed Pharmaceuticals Inc. director Nicole Lemerond was granted 1,750 employee stock options with an exercise price of $1.29, vesting in December 2026.

InMed Pharmaceuticals Inc. Director Neil A Klompas was granted 1,750 employee stock options with an exercise price of $1.29, vesting on December 18, 2026, or sooner.

InMed Pharmaceuticals Inc.'s Chief Financial Officer, Netta Jagpal, was granted 18,000 employee stock options with an exercise price of $1.29.

InMed Pharmaceuticals Inc. Chief Operating Officer Michael Woudenberg was granted 18,000 employee stock options with an exercise price of $1.29.

InMed Pharmaceuticals Inc. Director John Steven Bathery was granted 1,750 employee stock options with an exercise price of $1.29, vesting in one year.

InMed Pharmaceuticals Inc. reported the grant of 13,000 employee stock options to Senior VP Eric C. Hsu, aligning executive incentives.

InMed Pharmaceuticals Inc. CEO Eric A. Adams was granted 35,000 employee stock options with an exercise price of $1.29, vesting monthly over 36 months.

InMed Pharmaceuticals Inc. Director Andrew Hull was granted 1,750 employee stock options with an exercise price of $1.29.

InMed Pharmaceuticals Director Andrew Hull reported the expiration of 14 employee stock options.

InMed Pharmaceuticals Inc. CEO Eric A. Adams reported the expiration of 250 employee stock options on December 15, 2025.

InMed Pharmaceuticals Inc. Chief Operating Officer Michael Woudenberg reported the expiration of 60 employee stock options.

InMed Pharmaceuticals Inc. Senior VP Eric C. Hsu reported the disposition of 70 employee stock options with an exercise price of $1,397.97.

InMed Pharmaceuticals Director Neil A Klompas was granted 3,500 employee stock options with an exercise price of $2.1.

Andrew Hull, a director at InMed Pharmaceuticals, exercised stock options for 2 common shares on January 11, 2025.

InMed Pharmaceuticals' Senior VP & General Manager, Shane Aaron Johnson, was granted 1,500 stock options on December 20, 2024.

InMed Pharmaceuticals' Chief Financial Officer, Netta Jagpal, was granted 3,750 stock options on December 20, 2024, which vest monthly over 36 months.

Director Nicole Lemerond of InMed Pharmaceuticals Inc. was granted 550 stock options on December 20, 2024, which will vest on December 19, 2025, or immediately prior to the next Annual General Meeting.

InMed Pharmaceuticals' Chief Operating Officer, Michael Woudenberg, was granted 3,750 stock options on December 20, 2024, which vest monthly over 36 months.

Director Janet Grove of InMed Pharmaceuticals Inc. was granted 550 stock options on December 20, 2024, which will vest on December 19, 2025, or immediately prior to the next Annual General Meeting, whichever is sooner.